CTRM
Castor Maritime Inc.
There isn't enough reported data to score CTRM yet.
RKLB
Rocket Lab USA, Inc.
RKLB lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
CTRM Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Strong |
CTRM's profitability and balance sheet are currently healthy. There isn't enough data to rate its revenue and cash flow.
RKLB Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
RKLB's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
CTRM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 0.4x | $1.31 | — |
| Cheap | 0.5x | $1.82 | +39% |
| Fair | 1x | $3.44 | +163% |
| Expensive | 1.9x | $6.31 | +382% |
Historical ranges are pointers, not guarantees.
CTRM's PE is 0.4x, but its earnings don't support one, so it isn't a reliable read right now.
RKLB PE Valuation
RKLB has no meaningful PE right now: it lost money over the past year.
CTRM Forward outlook
There aren't enough analyst estimates for CTRM to show an outlook.
RKLB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect RKLB's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
CTRM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.32 | +$6.89 |
| Q4 2025 | $0.36 | -5.3% |
| Q4 2024 | $0.38 | -78% |
| Q4 2023 | $1.70 | -86% |
| Q2 2023 | $9.50 | +9.2% |
| Q4 2022 | $12.50 | +166% |
CTRM has the edge over RKLB in the latest year-over-year earnings comparison.
RKLB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.36 | +$0.03 |
| Q2 2026 | -$0.27 | +$0.19 |
| Q1 2026 | -$0.32 | +$0.09 |
| Q4 2025 | -$0.37 | +$0.01 |
| Q3 2025 | -$0.39 | -$0.02 |
| Q2 2025 | -$0.46 | -$0.11 |
| Q1 2025 | -$0.41 | -$0.04 |
| Q4 2024 | -$0.38 | $0.00 |
RKLB is still losing money, but less than at its worst: $0.36 per share over the past year, against $0.46 at its worst in mid-2025.
CTRM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $46.8M | +22% |
| Q4 2025 | $43.5M | +47% |
| Q2 2025 | $38.3M | +4.4% |
| Q4 2024 | $29.6M | -70% |
| Q2 2024 | $36.7M | -26% |
| Q4 2023 | $97.5M | -30% |
| Q2 2023 | $49.7M | -59% |
| Q4 2022 | $140M | +36% |
CTRM's revenue is recovering but still below its 2022 peak: $47M last quarter, up 28% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 156% | +81 points |
| Q4 2025 | 36% | +14 points |
| Q2 2025 | -90% | -111 points |
| Q4 2024 | -20% | -74 points |
| Q2 2024 | 75% | +33 points |
| Q4 2023 | 23% | -23 points |
| Q2 2023 | 22% | -8 points |
| Q4 2022 | 54% | +65 points |
CTRM has the edge over RKLB on profitability, with a higher operating margin.
RKLB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $267.8M | +73% |
| Q2 2026 | $234.1M | +62% |
| Q1 2026 | $200.3M | +63% |
| Q4 2025 | $179.7M | +36% |
| Q3 2025 | $155.1M | +48% |
| Q2 2025 | $144.5M | +36% |
| Q1 2025 | $122.6M | +32% |
| Q4 2024 | $132.4M | +121% |
RKLB has the edge over CTRM in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -30% | +8.5 points |
| Q2 2026 | -25% | +17 points |
| Q1 2026 | -28% | +20 points |
| Q4 2025 | -28% | +11 points |
| Q3 2025 | -38% | +12 points |
| Q2 2025 | -41% | -0.5 points |
| Q1 2025 | -48% | -1.9 points |
| Q4 2024 | -39% | +41 points |
RKLB's operating margin was −30% last quarter, up 8.5 points from the same quarter a year ago.
CTRM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$62.8M | -$58.6M |
| Q4 2025 | $13.6M | +$67.7M |
| Q2 2025 | -$4.2M | -118% |
| Q4 2024 | -$54.1M | -351% |
| Q2 2024 | $23.8M | +186% |
| Q4 2023 | $21.6M | +22% |
| Q2 2023 | $8.3M | -72% |
| Q4 2022 | $17.6M | +$64.4M |
CTRM's free cash flow was −$108M over the past year, against $71M the year before.
RKLB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$23.9M | +$45.5M |
| Q2 2026 | -$110.1M | -$54.8M |
| Q1 2026 | -$77.4M | +$5.5M |
| Q4 2025 | -$114.2M | -$90.2M |
| Q3 2025 | -$69.4M | -$27.5M |
| Q2 2025 | -$55.3M | -$26.9M |
| Q1 2025 | -$82.9M | -$61.1M |
| Q4 2024 | -$23.9M | +$28.7M |
RKLB has burned cash in almost every quarter: −$326M over the past year, against −$232M the year before.
CTRM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +502% | +48.5M shares |
| 1 year | +514% | +48.7M shares |
| 3 years | +242296% | +58.2M shares |
CTRM has 58M diluted shares, up 514% from a year ago.
RKLB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.6% | +22.6M shares |
| 1 year | +23% | +124M shares |
| 3 years | +35% | +168M shares |
| 5 years | +46% | +204M shares |
RKLB has the edge over CTRM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CTRM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2023 | -0.6x | Net Cash |
| Q2 2023 | 0.8x | Very low |
| Q4 2022 | 0.1x | Very low |
| Q2 2022 | 0.3x | Very low |
| Q4 2021 | 0.9x | Very low |
| Q2 2021 | 0.3x | Very low |
| Q4 2020 | 1.8x | Healthy |
CTRM has more cash than debt.
RKLB Net Leverage
RKLB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CTRM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.4 | Oversold |
| Stochastic | 4.8 | Oversold |
CTRM's weekly RSI is 29 (oversold) and its Stochastic is 5 (oversold).
RKLB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.8 | Neutral |
| Stochastic | 27.6 | Neutral |
RKLB's weekly RSI is 47 (neutral) and its Stochastic is 28 (neutral).
CTRM PE vs Industrials Sector
| Metric | CTRM | Sector median | Relative |
|---|---|---|---|
| PE | 0.4x | 24x | 98% below |
| PE % | 1 | 60 | 59 pts below |
CTRM is trading at 0.4x earnings, a 98% discount to the Industrials sector's median of 24x, though its earnings don't support one.
RKLB PE vs Industrials Sector
RKLB has no meaningful PE right now: it lost money over the past year.
CTRM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.65 | 21% below |
| 20 week MA | $1.98 | 34% below |
| 50 week MA | $2.04 | 36% below |
| 100 week MA | $2.17 | 40% below |
RKLB has stronger trend alignment. CTRM is above 0 of 4 weekly averages versus RKLB above 3 of 5.
RKLB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $61.4 | 4.3% above |
| 20 week MA | $68.1 | 5.9% below |
| 50 week MA | $77.6 | 17% below |
| 100 week MA | $56.5 | 13% above |
| 200 week MA | $31.4 | 104% above |
RKLB's trend is mixed: it's above three of its five weekly moving averages, and 104% above its 200-week average.
CTRM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $8.84 | $4.25 | -52% |
| 2024 | $4.25 | $2.88 | -32% |
| 2025 | $2.88 | $2.32 | -19% |
| 2026 YTD | $2.32 | $1.31 | -44% |
CTRM has finished every year since 2023 lower, and it's down 44% so far in 2026.
RKLB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.82 | $10.3 | +4.9% |
| 2021 | $10.3 | $12.0 | +17% |
| 2022 | $12.0 | $3.77 | -69% |
| 2023 | $3.77 | $5.53 | +47% |
| 2024 | $5.53 | $27.2 | +392% |
| 2025 | $27.2 | $70.7 | +160% |
| 2026 YTD | $70.7 | $64.1 | -9.3% |
RKLB has the edge over CTRM on returns for 2026, with the stronger performance.